ProCE Banner Activity


Evening With the Experts: Discussing the Rapidly Evolving Treatment Landscape for Early-Stage Breast Cancer


Watch this on-demand webcast from a June 2023 live symposium featuring Joyce O’Shaughnessy, MD; Komal Jhaveri, MD, FACP; and Mark E. Robson, MD, on the evolving role of biomarkers for perioperative breast cancer treatment with targeted therapy and immunotherapy.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 19, 2023

Expiration: June 18, 2024



Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Medical Oncologist
Texas Oncology/ Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Mark Robson

Mark Robson, MD

Professor of Medicine
Department of Medicine
Weill Cornell Medical College
Chief, Attending Physician
Clinical Genetics and Breast Medicine Services
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.


Merck Sharp & Dohme, LLC

Target Audience

This program is intended for medical oncologists and other healthcare professionals who care for patients with early-stage breast cancer.

Program Learning Goal

This activity aims to improve learners' knowledge, confidence, and competence to select and integrate new and emerging therapies into individualized treatment plans for early-stage breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence

  • Plan optimal neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC

  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Komal Jhaveri, MD, FACP: consultant/advisor/speaker: AbbVie, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/Stemline, Novartis, Olema Pharmaceuticals, Pfizer, Seattle Genetics, Sun Pharma Advanced Research Company Ltd, Taiho Oncology; researcher (paid to institution): AstraZeneca, Context Therapeutics, Debio Pharmaceuticals, Genentech/Roche, Gilead, Lilly/Loxo Oncology, Merck, Novartis, Pfizer, PUMA Biotechnology, Zymeworks.

Joyce O'Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Caris, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, Exact Sciences, Fishawack Health, G1 Therapeutics, GlaxoSmithKline, Genentech, Gilead Sciences, Immunomedics, Incyte Corporation, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, PUMA Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, Synthon, Veru.

Mark E. Robson, MD: researcher: AstraZeneca, Merck, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 19, 2023, through June 18, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.